Indications of Rituximab in autoimmune diseases

Sanz, Iñaki

doi:10.1016/j.ddstr.2009.10.001

Cited by 29 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following the clinical use of specific antibodies for B-cell depletion in the treatment of various human autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, and systemic lupus erythematosus (SLE), it soon became evident that the functions of B cells were found to be multiple, including functions affecting T cells [59].…”

Section: Changes In the Expression Of B-cell Surface Molecules May Afmentioning

confidence: 99%

Impairment of B-cell functions during HIV-1 infection

Amu

Ruffin

Réthi

et al. 2013

Aids

View full text Add to dashboard Cite

A variety of B-cell dysfunctions are manifested during HIV-1 infection, as reported early during the HIV-1 epidemic. It is not unusual that the pathogenic mechanisms presented to elucidate impairment of B-cell responses during HIV-1 infection focus on the impact of reduced T-cell numbers and functions, and lack of germinal center formation in lymphoid tissues. To our understanding, however, perturbation of B-cell phenotype and function during HIV-1 infection may begin at several different B-cell developmental stages. These impairments can be mediated by intrinsic B-cell defects as well as by the lack of proper T-cell help. In this review, we will highlight some of the pathways and molecular interactions leading to B-cell impairment prior to germinal center formation and B-cell activation mediated through the B-cell receptor in response to HIV-1 antigens. Recent studies indicate a regulatory role for B cells on T-cell biology and immune responses. We will discuss some of these novel findings and how these regulatory mechanisms could potentially be affected by the intrinsic defects of B cells taking place during HIV-1 infection.

show abstract

Section: Changes In the Expression Of B-cell Surface Molecules May Afmentioning

confidence: 99%

Impairment of B-cell functions during HIV-1 infection

Amu

Ruffin

Réthi

et al. 2013

Aids

View full text Add to dashboard Cite

show abstract

“…B cells participate in antigen presentation, regulatory signaling to T cells and provide regulatory cytokine signals to dendritic cells [36;37]. The majority of antibody-forming B cells are plasma cells which do not express CD20 and are therefore not susceptible to rituximab depletion [25]. Animal models suggest that reductions in autoantibody levels may be due to removal of short-lived antibody-forming cells or depletion of plasmablast precursors [38].…”

Section: Discussionmentioning

confidence: 99%

An Open-Label Trial Of Rituximab Therapy In Pulmonary Alveolar Proteinosis

Marshall¹,

Malur²,

Barna³

et al. 2011

A46. Interstitial Lung Disease: Pulmonary Alveolar Proteinosis and Lymphangioleiomyomatosis: Moving Forward With Diagnosis and

View full text Add to dashboard Cite

Rituximab, a monoclonal antibody directed against the B-lymphocyte antigen CD20, has shown promise in several autoimmune disorders. Pulmonary Alveolar Proteinosis (PAP) is an autoimmune disorder characterized by autoantibodies to Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF).An open label proof-of-concept Phase II clinical trial was conducted in 10 PAP patients. Intervention consisted of two intravenous infusions of rituximab (1000mg), fifteen days apart. Bronchoalveolar lavage (BAL) and peripheral blood samples were collected.The primary outcome was improvement in arterial blood oxygenation. Both PaO 2 and A-a gradient on room air improved in 7/9 patients completing the study. Lung function and HRCT scans, secondary outcomes, also improved. Peripheral blood CD19+ B-lymphocytes decreased from 15±2% to <0.05% (n=10) fifteen days post therapy. This decrease persisted for 3 months in all patients; at six months CD19+ were detected in 4/7 patients (mean 5±2). Total anti-GM-CSF IgG levels from baseline to 6 months were decreased in BAL fluids (n=8), but unchanged in sera (n=9).In this PAP cohort, (1) rituximab was well-tolerated and effectively ameliorated lung disease; (2) reduction in anti-GM-CSF IgG levels in the lung correlated with disease changes suggesting that disease pathogenesis is related to autoantibody levels in the target organ.

show abstract

“…6,7 It has received formal FDA regulatory approvals for treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia and, in combination with methotrexate, as second-line therapy for adult patients with moderate to severe rheumatoid arthritis. 8 Rituximab received its initial FDA approval for marketing in the USA in 1997 and in the European Union in 1998.…”

Section: Innovations In Monoclonal Antibody (Mab) Productionmentioning

confidence: 99%

Rituximab and biosimilars – equivalence and reciprocity

Qureshi¹,

Magwood²,

Singh³

et al. 2013

View full text Add to dashboard Cite

Cancer is a debilitating disease affecting millions of people daily. Over the years, cancer treatment has advanced in leaps and bounds. Antibodies are important breakthrough therapeutic agents for cancer. These agents, proteins produced by B lymphocytes of the immune system in response to antigens, bind to receptors on cell surfaces so that the antigen–antibody complexes can be recognized and destroyed by phagocytes. While each B cell synthesizes only one kind of antibody, an entire population of different types of B cells and their respective antibodies are produced in response to various antigens to which the organism had been exposed. However, to be useful clinically, substantial amounts of a single antibody must be generated from a single ancestral B cell. These antibodies produced by a specific population of B cells are the monoclonal antibodies that have become the cornerstone of treatment for cancer and many immunologic illnesses. The purpose of this report is to provide an overview of the clinical development of biosimilars in clinical oncology, focusing on rituximab and like biosimilars.

show abstract

Indications of Rituximab in autoimmune diseases

Cited by 29 publications

References 47 publications

Impairment of B-cell functions during HIV-1 infection

Impairment of B-cell functions during HIV-1 infection

An Open-Label Trial Of Rituximab Therapy In Pulmonary Alveolar Proteinosis

Rituximab and biosimilars – equivalence and reciprocity

Contact Info

Product

Resources

About

Indications of Rituximab in autoimmune diseases

Cited by 29 publications

References 47 publications

Impairment of B-cell functions during HIV-1 infection

Impairment of B-cell functions during HIV-1 infection

An Open-Label Trial Of Rituximab Therapy In Pulmonary Alveolar Proteinosis

Rituximab and biosimilars &ndash; equivalence and reciprocity

Contact Info

Product

Resources

About

Rituximab and biosimilars – equivalence and reciprocity